Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-06
1998-06-09
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530313, 530328, A61K 3824, A61K 3804, C07K 723
Patent
active
057634041
ABSTRACT:
Antide is the decapeptide, N-Ac-D-2-Nal,D-pClPhe, D-3-Pal, Ser,NicLys, D-NicLys, Leu, ILys, Pro, D-Ala,NH.sub.2 which is an antagonist of luteinizing hormone releasing hormone (LHRH). This decapeptide, like others of the present invention, has high antiovulatory activity (AOA) and releases negligible histamine. Antide is scheduled for scale-up, safety testing and evaluation in the experimental primate and in clinical medicine. Numerous other peptides having structures related to Antide were prepared and tested. These peptides had variations primarily in positions 5, 6, 7, and 8. Of these, N-Ac-D-2-Nal, D-pClPhe,D-3-Pal,Ser,PicLys,cis-DPzACAla,Leu,ILys,Pro,D-Ala-NH.sub.2 was one of the most potent and had higher antiovulatory activity than Antide, i.e. 73%/0.25 ug and 100%/0.5 ug vs. 36%/0.5 ug and 100%/1.0 ug. Antide showed significant, (p<0.001) duration of action, when injected at a dose Antide showed oral AOA at 600 ug (73%) and at 1200 ug (100%) with negligible difference being found between water and corn oil oral formulations.
In the antagonists prepared according to the present invention, arginine and its derivatives were not utilized. Lysine was converted into derivatives with acyl groups or with alkyl groups on the E-amino group. The amino acid ornithine was acylated or alkylated on the d-amino group. Both the L- and D- forms of lysine and the L-form of ornithine were used in synthesizing these acyl and alkyl derivatives. Structurally related intermediates were also synthesized. All together, many new peptides were synthesized by the basic and minimal concepts of ten variables for anti-ovulation activity and ten variables for histamine release, which may be independent or partially overlapping. On such a basis, the number of such peptides that can be designed becomes overwhelming, and every reasonable priority must be considered to reduce the number of peptides to be synthesized in the hope that a discovery will be realized.
REFERENCES:
patent: 4431635 (1984-02-01), Coy et al.
patent: 4444759 (1984-04-01), Rivier et al.
patent: 4504414 (1985-03-01), Folkers et al.
patent: 4530920 (1985-07-01), Nestor et al.
patent: 4647653 (1987-03-01), Coy
patent: 4652550 (1987-03-01), Rivier et al.
patent: 4801577 (1989-01-01), Nestor, Jr. et al.
patent: 4845077 (1989-07-01), Hodgen
patent: 4851385 (1989-07-01), Roeske
patent: 5140009 (1992-08-01), Haviv et al.
patent: 5180711 (1993-01-01), Hodgen
patent: 5300492 (1994-04-01), Haviv et al.
patent: 5413990 (1995-05-01), Haviv et al.
"Recovery of Pituitary-Gonadal Function in Male and Female Rats After Prolonged Administration of a Potent Antagonist of Luteinizing Hormone-Releasing Hormone (SB-75)," Lazaro Bokser et al., Neuroendocrinology, Aug. 1991, pp. 136-145.
"Blockade of Central and Peripheral Luteinizing Hormone-Releasing Hormone (LHRH) Receptors in Neonatal Rats With A Potent LHRH-Antagonist Inhibits the Morphofunctional Development of the Thymus and Maturation of the Cell-Mediated and Humoral Immune Responses," M. C. Morale et al., Endocrinology, vol. 128, No. 2, Feb. 1991, pp. 1073-1085.
"Effects of LHRH Antagonist Administration to Immature Male Rats on Sexual Development," H. M. Van Den Dungen et al., Physiology & Behavior, vol. 46, 1989, pp. 779-785.
"The Effects of LH-RH Inhibitory Analogues in the Non-Human Primate. Basic Studies in Contraception and Their Direct Applications for Future Clinical Uses in Both Sexes," Ricardo H. Asch, M.D., LHRH and Its Analogues, 1984, pp. 188-202.
"Effects of a Luteinizing Hormone-Releasing Hormone Antagonist in Late-Juvenile Female Rats: Blockade of Follicle Growth and Delay of First Ovulation Following Suppression of Gonadotropin Concentrations," H. M. A. Meijs-Roelofs et al., Biology of Reproduction, vol. 43, No. 4, Oct. 1990, pp. 607-613.
Channabasaviah, et al., New Potent Agonist and Antagonist Analogs of Luteinizing Hormore Release Hormore, pp. 803-806.
Hautklinik, et al., Archiv der Pharmazie, vol. 7, pp. 330-338 (1958).
Chemical Abstract, 10B-Aliphatic Compounds, pp. 11237-11238, (U.S. Patent No. 2,872,484)(1959).
Benoiton, Canadian Journal of Chemistry, vol. 42, pp. 2043-2047 (1964).
Bernardi, et al. J. Pharm. Pharmac., vol. 19, pp. 95-101 (1967).
Tjoeng, et al., Chem. Ber., vol. 108, pp. 862-874 ( 1975).
Prasad, et al., Journal of Medicinal Chemistry, vol. 19, pp. 492-495 (1976).
Humphries, et al., Journal of Medicinal Chemistry, vol. 21,120-123 (1978).
Channabasaviah, et al., Biochem and Biohpys Research Comm., vol. 86, No. 4, pp. 1266-1275 (1979).
Nikolis, et al., Peptides, vol 5, pp. 1001-1006 (1984).
Fife and Przystas, J. Am. Chem. Soc., vol. 4, pp. 1041-1047 (1985).
Karten and Rivier, J. Endocrine Rev., vol. 7, No. 1, pp. 44-66 (1986).
Rivier et al., J. Med. Chem., vol. 29, pp. 1846-1851 (1986).
Karten, Marvin J., J. Endocrine Rev., vol. 7, No. 1, pp. 44-66 (1986).
Roeshe, et al. Proceedings of 9th American Peptide Sym Pierce Chem. Co., Rockford, IL, pp. 561-564 (1986).
Folkers, et al., Z. Naterfarsch, B. Chem. Sci. 42(1), pp. 101-106 (1987).
Hocart, S.J., et al. J. Med. Chem. 30(10), pp. 1910-1914, Oct. (1987).
Ljungvist, et al., Biochem Biophys. Res. Commun., vol. 148, No. 2, pp. 849-856, (1987).
Hocart, S. J., et al. J. Med. Chem. 30, pp. 739-743 (1987).
Karten et al., Contraceptive and Therapeutic Applications, Part 2 eds., Vickery et al., pp. 179-190 (1987).
Bajusz et al., Proc. Natl. Acad. Sci. USA, vol. 85, pp. 1637-1641 (1988).
Rivier, et al., Coll. Soc. Etides Fertil., vol. 26, pp. 25-31 (1988).
Dutta, Anand S., Drugs of the Future, vol. 13, No. 8, pp. 761-767 (1988).
River, et al., J. Med. Chem., vol. 29, pp. 1846-1851 (1986).
Phillips, et al., Life Sciences, vol 43, pp. 883-888 (1988).
PCT International Search Report, mailed Jan. 27, 1989.
Nestor, J.J., Tahilramani, R., Ho, T. L., McRae, G. I. & Vickery, B.H. (1988) J. Med. Chem. vol. 31, No. 1, pp. 65-72.
Rivier, J. Kupryszewski, G., Varga, J., Porter, J., Rivier, C., Perrin, M., Hagler, A., Struthers, S., Corrigan, A. & Vale, W. (1988) J. Med. Chem. vol. 31, No. 3, pp. 677-682.
Folkers, K., Bowers, C.Y., Shieh, H.-M., Liu, Y.-Z., Xiao, S.-B., Tang, P.-F.L. & Chu, J.-Y. (1984) Biochem. Biophys, Res. Commun., vol. 123, No. 3, pp. 1221-1226.
Miyamoto, K., Hasegawa, Y., Nomura, M., Igarashi, M., Kanagawa, K. & Matsuo, H. (1984) Proc. Natl. Acad. Sci, USA, vol. 81, No. 12, 3874-3878.
Sherwood, N., Eiden, L., Brownstein, M., Spiess, J., Rivier, J., & Vale, W. (1983) Proc. Natl. Acad. Sci. USA, vol. 80, No. 9, pp. 2794-2798.
Sherwood, N.M., Sower, S.A., Marshak, D.R., Fraser, B.A. & Brownstein, M.J. (1986) J. Biol. Chem. vol. 26, No. 11, pp. 4812-4819.
Roeske, R.W., Chaturvedi, N.C., Hrinyo-Pavlina, T., Kowalczuk, M., LHRH and Its Analogs: Contraceptive and Therapeutic Applications Part 2, eds. Vickeryk, B.H. & Nestor, J.J., Jr., (MTP Press Ltd., Lancaster, England) pp. 17-24.
Karten, et al. (1987), In Vitro histamine release with LHRH analogs;.
Bernardi, et al. (1967), J. Pharm. Pharmac., 19:95-101;.
Hautklinik, et al., (1958), Archiv der Pharmazie, No. 7:330-338;.
Fife and Przystas, (1985), J. Am. Chem. Soc., 4:1041-1047;.
Prasad, et al., (1976), Journal of Medicinal Chemistry, 19:492-495;.
Benoiton, (1964), Canadian Journal of Chemistry, 42:2043-2047;.
Chemical Abstract, (1959), 10B-Aliphatic Compunds, pp. 11237-11238 (U.S. patent No. 2,872,484);.
Tjoeng, et al., (1975), Chem. Ber., 108:862-874;.
Humphries, et al. (1978), Journal of Medicinal Chemistry, 21:120-123;.
Karten, Marvin J., Endocrine Rev., vol. 7, No. 1, 1986, pp. 44-66.
Dutta, Anand S., Drugs of the Future, vol. 13, No. 8, 1988, pp. 761-767.
Phillips, et al., Life Sciences, vol. 43, 1988, pp. 883-888.
Rivier, et al., J. Med. Chem., 1986, 29, 1846-1851.
Rivier et al., (1986) New Effective Gonadotropin Releasing Hormone Antagonists with Minimal Potency for Histamine Release In Vitro, J. Med. Chem. 29:1846-1851.
Karten and Rivier, (1986) Gonadotropin-Releasing Hormone Analog Design. Structure-Function Studies Toward the Development of Agonists and Antagonists: Rationale and Perspective, Endocrine Reviews 7(1):44-66.
Ljungqvist et al., (1987) Design,
Bowers Cyril Y.
Feng Dong-Mei
Folkers Karl A.
Kubota Minoru
Ljungqvist Anders
Marshall S. G.
Tsang Cecilia J.
LandOfFree
Methods for using LHRH antagonists with low histamine release does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for using LHRH antagonists with low histamine release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using LHRH antagonists with low histamine release will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2199150